|
Summary Information: Acorda Therapeutics Inc. Common Stock NASDAQ:ACOR |
  [email protected] |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
__The following are links to various summary and news pages for __Acorda Therapeutics Inc. Common Stock [ ACOR ]. __Note: Some Links might not have information for the company. |
|